DrugPatentWatch
Depends
Confidence: Low
Buy only if you run portfolio, BD, or litigation strategy inside a pharma company and need patent-cliff forecasting; the free trial makes testing cheap.
Comparison
DrugPatentWatch vs Evaluate Pharma
Evaluate Pharma
Starting report…
Pick DrugPatentWatch when
- Pharma portfolio and lifecycle strategy teams
- Generic-entry (ANDA) planners
- Litigators tracking patent challenges
When DrugPatentWatch is not a fit
- Hospitals, clinics, pharmacies . clinical needs, not market intelligence
- Small teams without analysts to interpret patent data
- Anyone outside biopharma . zero relevance
- Buyers needing transparent self-serve pricing upfront
Sources
- DrugPatentWatch homepagedrugpatentwatch.comofficial
- Security page checkdrugpatentwatch.comsecurity
- DrugPatentWatch citations in primary literaturedrugpatentwatch.comofficial
- Blog: Forecast generic launch dates using patent intelligencedrugpatentwatch.comofficial
news
- GeneOnline: Pharma patent strategies reportgeneonline.comnews
- LinkedIn post on ANDA review timelineslinkedin.comnews
- Hatena bookmark from 2011b.hatena.ne.jpnews
official